Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro

Although the mechanistic target of rapamycin (mTOR) inhibitor, everolimus, has improved the outcome of patients with renal cell carcinoma (RCC), improvement is temporary due to the development of drug resistance. Since many patients encountering resistance turn to alternative/complementary treatment...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Juengel, Eva, Maxeiner, Sebastian, Rutz, Jochen, Justin, Saira, Roos, Frederik, Khoder, Wael, Tsaur, Igor, Nelson, Karen, Bechstein, Wolf O., Haferkamp, Axel, Blaheta, Roman A.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356730/
https://ncbi.nlm.nih.gov/pubmed/27863441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13421
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars